Literature DB >> 22418399

Synthetic cannabinoid use: recognition and management.

Daniel Castellanos1, Gabriel Thornton.   

Abstract

In the past few years, synthetic cannabinoid products have been increasingly used by adolescents and young adults. These products are marketed as herbal or aromatic incense and potpourri, but their psychoactive properties appear to be due to the addition of synthetic cannabinoids. When smoked, they can produce significant psychoactive and physical effects similar to cannabis. Changes in cognition, behavioral disturbances, alterations in mood, and perceptual changes have been reported. An emerging body of literature indicates that use of these products is associated with anxiety and other negative mood changes not typical of cannabis intoxication. Use of synthetic cannabinoid products has been associated with new onset psychosis or exacerbation of pre-existing psychosis, although current evidence cannot establish a definitive link between synthetic cannabinoids and psychosis. Clinicians should suspect synthetic cannabinoid product use if a patient: 1) presents with signs and symptoms consistent with cannabis use, 2) has negative routine urine toxicology screens, 3) is in a situation in which his or her urine is being routinely monitored for illicit substance use, and/or 4) presents with otherwise unexplained sudden onset psychosis. To make the diagnosis, clinicians should become familiar with the effects of synthetic cannabinoid use and have a high index of suspicion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22418399     DOI: 10.1097/01.pra.0000413274.09305.9c

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  14 in total

Review 1.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 2.  [Not all drugs are the same].

Authors:  L S Weilemann
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-08-24       Impact factor: 0.840

3.  New challenges of the pediatric emergency department: synthetic cannabinoids.

Authors:  Sinan Oğuz; Funda Kurt; Deniz Tekin; Emine Suskan
Journal:  Turk Pediatri Ars       Date:  2014-12-01

Review 4.  Approach to cannabis use disorder in primary care: focus on youth and other high-risk users.

Authors:  Suzanne D Turner; Sheryl Spithoff; Meldon Kahan
Journal:  Can Fam Physician       Date:  2014-09       Impact factor: 3.275

Review 5.  Spicing things up: synthetic cannabinoids.

Authors:  Max Spaderna; Peter H Addy; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

6.  The effects of synthetic cannabinoids on executive function.

Authors:  K Cohen; M Kapitány-Fövény; Y Mama; M Arieli; P Rosca; Z Demetrovics; A Weinstein
Journal:  Psychopharmacology (Berl)       Date:  2017-02-03       Impact factor: 4.530

7.  High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use.

Authors:  Sameir Alhadi; Anupama Tiwari; Rais Vohra; Roy Gerona; Janak Acharya; Kathryn Bilello
Journal:  J Med Toxicol       Date:  2013-06

Review 8.  Marijuana: current concepts(†).

Authors:  Donald E Greydanus; Elizabeth K Hawver; Megan M Greydanus; Joav Merrick
Journal:  Front Public Health       Date:  2013-10-10

9.  Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients.

Authors:  Merih Altintas; Leman Inanc; Gamze Akcay Oruc; Selim Arpacioglu; Huseyin Gulec
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-02       Impact factor: 2.570

Review 10.  Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.

Authors:  Aviv M Weinstein; Paola Rosca; Liana Fattore; Edythe D London
Journal:  Front Psychiatry       Date:  2017-08-23       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.